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O-GlcNAcase (OGA) is the only enzyme responsible for removing N-acetyl glucosamine
(GlcNAc) attached to serine and threonine residues on proteins. This enzyme plays a
key role in O-GlcNAc metabolism. However, the structural features of the sugar moiety
recognized by human OGA (hOGA) remain unclear. In this study, a set of glycopeptides
with modifications on the GlcNAc residue, were prepared in a recombinant full-length
human OGT-catalyzed reaction, using chemoenzymatically synthesized UDP-GlcNAc
derivatives. The resulting glycopeptides were used to evaluate the substrate specificity
of hOGA toward the sugar moiety. This study will provide insights into the exploration
of probes for O-GlcNAc modification, as well as a better understanding of the roles of
O-GlcNAc in cellular physiology.
Keywords: O-GlcNAcylation, O-GlcNAcase, sugar moiety, GlcNAc derivatives, substrate specificity
INTRODUCTION
Protein glycosylation is an important protein post-translational modification in various organisms
and is critical for a wide range of biological processes. Defective or aberrant glycosylation can lead
to serious cellular dysfunction or diseases in humans (Wells et al., 2001). O-GlcNAcylation is a
single N-acetylglucosamine beta-linked to the serine or threonine residues of some nucleic acids
and cytoplasmic proteins, and is essential for multiple cellular signaling cascades, including gene
transcription, protein translation, cell cycle, and nutrient sensing (Chen et al., 2013; Ferrer et al.,
2014; Hardiville and Hart, 2014). By affecting the stability, activity, or interactions of key signaling
proteins, O-GlcNAcylation is a novel and vital factor in the cause of diseases such as diabetes,
cancer, and neurodegeneration (Yuzwa et al., 2012; Yuzwa and Vocadlo, 2014; Zhu et al., 2014).
Because of the importance of O-GlcNAc and its crucial role in disease pathology, the enzymes
controlling O-GlcNAcylation levels are considered to be therapeutic targets.
O-GlcNAcylation is a dynamic reversible process, the addition and removal of GlcNAc residues
from a protein is regulated by only two enzymes. Uridine diphosphate-N-acetyl-D-glucosamine:
polypeptidyl transferase (OGT) is responsible for transferring a single GlcNAc from
uridine diphosphate-α-N-acetyl-D-glucosamine (UDP-GlcNAc) to proteins. O-GlcNAcase (OGA)
removes GlcNAc from glycoproteins. Substrate promiscuity of OGT and OGA has been shown
to be valuable for enzymatic catalysis and O-GlcNAcylation level control. The substrate specificity
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of human OGT (hOGT) has been widely investigated and the
hOGT crystal structure has been solved (Lazarus et al., 2011).
Among the 26 UDP-sugar derivatives, 4 (UDP-GlcNPr, UDP-
6-deoxy-GlcNAc, UDP-4-deoxy-GlcNAc and UDP-6-deoxy-
GalNAc) were reported to highly glycosylate peptides via
sOGT-catalyzed glycosylation (Ma et al., 2013). For peptide
acceptor recognition, 3 positions (−2, −1, and +2) in the
peptide sequence are vital for O-GlcNAcylation, and uncharged
amino acids are preferred and show high reactivity (Liu et al.,
2014). Recently, several research groups solved the structure of
hOGA and revealed that hOGA existed as an unusual arm-in-
arm homodimer. The residues of hOGA on the cleft surface
enabled broad interactions with peptide substrates, indicating the
important role of the peptide structure in the recognition mode
(Elsen et al., 2017; Li et al., 2017; Roth et al., 2017). However,
partly because of the difficulties in obtaining glycopeptides
with modified GlcNAc residues, structure determination during
GlcNAc-recognition by hOGA remains unclear.
We previously evaluated chemoenzymatic synthesis and
purified oligosaccharides and glycopeptides (Wen et al., 2016a,b;
Wu et al., 2016; Wang et al., 2018). As an extension
of these studies, glycopeptides containing different GlcNAc
derivatives were successfully synthesized and purified. Further,
we investigated the substrate specificity of hOGA and found
that hOGA was less promiscuous in tolerating substrates with
modified GlcNAc.
RESULTS
Synthesis of GlcNAc Derivatives
GlcNAc and GalNAc were purchased from Carbosynth (San
Diego, CA, USA). GlcNPh, GlcNGc, GlcNTFA, and 6-N3-
GlcNAc were gifted from Dr. Xi Chen’s lab (UC Davis, USA).
4-Deoxy-GlcNAc and GlcNAz were synthesized according to
our previous report (Li et al., 2016). The other three new
compounds, GlcNPr, 4-OMe-GlcNAc, and 6-deoxy-GlcNAc,
were synthesized for the first time in this study (Figure 1).
GlcNPr was generated in the presence of propionyl chloride
FIGURE 1 | Synthetic methods of compounds: (A) GlcNPr, (B) 4-OMe-GlcNAc, and 6-deoxy-GlcNAc.
and pyridine after global deprotection. A convergent route
was designed to synthesize 6-deo-GlcNAc and 4-OMe-GlcNAc;
GlcNAc as the starting material was first protected with
benzylidine and then subjected to 1,3-diacetylation to afford
intermediate 5. Selective deprotection of benzylidine was carried
out in the presence of NBS and calcium sulfate to afford 6. The
desired target compound 8 was obtained after reduction of the
bromide and full deacetylation. For 4-OMe-GlcNAc, bezylidine
in 5 was removed and selective acetylation of the 6-OH freed the
4-OH, which was O-methylated in the presence of iodomethane
and silver oxide. 11 was obtained after global deprotection.
Protein Expression and Purification
According to previous studies, we overexpressed Bifidobacterium
infantis N-acetylhexosamine 1-kinase ATCC#15697 (BiNahK),
human UDP-N-acetylgalactosamine pyrophosphorylase
(hAGX1), human OGT (ncOGT), and human OGA (hOGA)
in Escherichia coli (Gross et al., 2005; Guan et al., 2010; Li
et al., 2011, 2012). Enzymes were expressed by induction with
1mM of isopropyl 1-thio-β-D-galactopyranoside followed
by incubation at 16◦C for 24 h with vigorous shaking (200
rpm). After purification, 15mg ncOGT, 20mg hOGA, 40mg
BiNahK, and 20mg hAGX1 were obtained from 1 L of an E. coli
culture. As shown in Figure S1, enzymes with an N-terminal
His6 tag showed 80% purity with a high yield. The apparent
molecular weights of the enzymes according to SDS-PAGE were
well-correlated with the calculated molecular weights of each
protein.
Production of Glycopeptides and
Determination of Substrate Specificity of
OGT
UDP-GlcNPh, UDP-GlcNGc, UDP-GlcNTFA, and UDP-6-N3-
GlcNAc were synthesized as reported previously (Chen et al.,
2011). Other sugar nucleotides were obtained through a
chemoenzymatic strategy by chemical synthesis of GlcNAc
derivatives, which were used as the substrates in a one-pot two-
enzyme system containing BiNahK and hAGX1 (Figure 2A).
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FIGURE 2 | (A) Production of glycopeptides by hOGT-catalyzed reaction using chemoenzymatically synthesized UDP-GlcNAc derivatives. (B) The structures of
glycopeptide derivatives used in the study.
FIGURE 3 | The HPLC and MALDI-TOF profile for OGT (A) and OGA (B) reactions toward UDP-GlcNAc substrates. * represents the glycopeptide peak.
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TABLE 1 | The yields of OGT and OGA reactions.
UDP-GicNAc
derivatives
Glycopeptid
yield(%)
OGA hydrolysis
yield(%)
UDP-GicNAc
derivatives
Glycopeptide
yield (%)
OGA hydrolysis
yield (%)
78.5 ± 1.2 NDb 56.0 ± 0.9 5.4 ± 0.3
81.2 ± 1.1 3.0 ± 0.8 92.6 ± 3.2 96.3 ± 1.6
49.1 ± 2.5 NDb 58.9 ± 0.4 47 ± 0.6
58.5 ± 1.1 NDb 99.4 ± 0.8 NDb
63.1 ± 0.9 NDb 23.8 ± 1.2 62.2 ± 2.4
NDb: not detected
All UDP-sugars produced were characterized by capillary
electrophoresis and matrix-assisted laser desorption/ionization
(MALDI)-time-of-flight mass spectrometry (Figure S3).
The peptide substrate (YAVVPVSK) was synthesized based
on the Fmoc-strategy using a Liberty Blue Peptide Synthesizer
and purified by high-performance liquid chromatography
(HPLC) (Liu et al., 2014) (Figure S4). A set of glycopeptides
carrying modifications on the GlcNAc residue were subsequently
prepared in a recombinant full-length hOGT-catalyzed reaction
using chemoenzymatically synthesized UDP-GlcNAc derivatives
(Figure 2A). The hOGT enzyme reactions were carried out at
37◦C for 2 h in a volume of 100 µL containing 1mM peptide,
3mMUDP-GlcNAc analogs, and 50µg ncOGT in buffer (50mM
Tris-HCl, pH 7.5, 10mM Mg2+). The reaction was boiled, and
the products were subjected to HPLC purification and yield
quantification (Table 1). Each peak was collected and identified
based on MALDI. For example, GlcNAc showed a peak at
18.6min and was characterized as GlcNAc-peptide with m/z
= 1088.017, while the peak at 19.7min was characterized as
a peptide with m/z = 862.954 (M+H) and 884.943 (M+Na)
(Figure 3A). The retention time of the pure peptide was 19.7min,
while the GlcNAc-peptide showed a retention time of 18.6min
because of the increased polarity of GlcNAc (Figure 3A).
Moreover, the OGT reaction efficiency was calculated as the
glycopeptide yield (Ya%). The yield was calculated with the
formula Ya = S1/(S1+S2), where S1 and S2 are the integrated
areas of the glycopeptide and peptide peaks, respectively
(Table 1). The HPLC profile of the OGT and OGA reaction on
the peptide are detailed in the Supporting Materials (Figure S2).
By utilizing this method, 10 glycopeptide derivatives (5
glycopeptides with C2-modified GlcNAc, 3 glycopeptides
with C4-modified GlcNAc, and 2 glycopeptides with C6-
modified GlcNAc) were produced (Figure 2B), purified
by HPLC, and characterized by MALDI (Figure S5). All
UDP-GlcNAc derivatives were good substrates for hOGT except
for UDP-6-N3-GlcNAc, which resulted in only 23.8% yield in
vitro (Table 1). Notably, hOGT was the full-length isoform
with 13.5 tetratricopeptide repeats (TPRs), which showed
higher activity than sOGT (short OGT with 2.5 TPRs). For
example, when sOGT was used, six UDP-GlcNAc derivatives
(UDP-GlcNGc, UDP-GlcNAz, UDP-GlcNTFA, UDP-GlcNPh,
UDP-6-N3-GlcNAc, and UDP-GalNAc) used as the substrates
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produced <1% yield (Ma et al., 2013). In comparison, over
49% yield was obtained when full-length hOGT was used.
The crystal structures of the N-terminal domain of full-length
hOGT containing the first 11.5 TPRs, showed that the conserved
asparagine residues in the TPR domain directly contacted the
substrates, supporting the role of the TRP domains in initial
recognition and substrate specificity determination (Jinek et al.,
2004). In summary, in addition to preparing glycopeptides, we
found that full-length hOGT is a more efficient catalyst than the
previously reported short sOGT.
OGA Substrate Specificity Assay
The glycopeptide peaks from OGT reactions were collected
and lyophilized for the hOGA substrate specificity assay. The
hOGA reaction was conducted overnight in a volume of 100
µL containing the glycopeptides, MgCl2 (20mM), Tris–HCl
(200mM), and recombinant hOGA (0.1mg). The reaction
mixture was boiled and centrifuged before HPLC separation.
Each peak was collected and characterized by MALDI. When
the GlcNAc-peptide was treated with hOGA, efficient hydrolysis
activity of hOGA and a single peptide peak were observed
(Figure 3B). The hOGA hydrolysis yield (Yb%) was calculated
using the formula Yb = S2/(S1+S2), where S1 and S2 are
the integrated areas of the glycopeptide and peptide peaks,
respectively. The HPLC profiles of the OGT and OGA reaction
on the peptide are described in detail in the Supporting Materials
(Figure S2). The GlcNAz-peptide and 6-N3-GlcNAc-peptide
were well-tolerated by hOGA, and other glycopeptide derivatives
significantly decreased the efficiency of hOGA, showing <10%
hydrolysis yield (Table 1). The results revealed that hOGA
had a relatively strict recognition for the sugar moiety in the
glycopeptides, thus exhibiting limited activities for glycopeptide
derivatives with C2, C4, and C6 modifications on GlcNAc.
CONCLUSION
Glycopeptides containing different GlcNAc derivatives were
successfully synthesized in a recombinant full-length hOGT-
catalyzed reaction, using chemoenzymatically synthesized UDP-
GlcNAc derivatives. We also found that full-length hOGT
is a more efficient catalyst than sOGT, as over a 49-fold
yield was observed when hOGT was used. The resulting
glycopeptides were used to investigate the substrate specificity
of hOGA toward the sugar moiety. hOGA was less promiscuous
in tolerating glycopeptide substrates with modified GlcNAc,
and changes in the C2, C4, and C6 positions of GlcNAc
partially affected its recognition. Interestingly, OGT and OGA
possessed different levels of tolerance to the same sugar
moiety, such as GlcNPh, GlcNTFA, and 4-OMe-GlcNAc.
Therefore, the acquired GlcNAc derivatives, which were well-
recognized by OGT but not hydrolyzed by OGA, may increase
the O-GlcNAcylation level in vivo when the peracetylated
compound is metabolically incorporated. Indeed, our group
developed an OGA-resistant probe, peracetylated 4-deoxy-N-
azidoacetylglucosamine (Ac3-4-deoxy-GlcNAz), which can be
used as a potent tool for O-GlcNAcylation detection and the
identification of O-GlcNAcylated proteins (Li et al., 2016). Thus,
OGA-resistant GlcNAc substrates show potential as excellent
probes for investigating O-GlcNAcylation and elucidating their
importance in cellular events.
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